Insights into a rare clinical phenomenon: Isolated native valve endocarditis subsequent to transcatheter prosthetic valve implantation Authors: Sujoy Khasnavis, Stefan Makrievski, Caroline Delbourgo Patton, Majd Alhuarrat, Shaunak Mangeshkar, Robert Faillace, Michael Grushko Published: 2026 ABSTRACT AbstractIntroductionProsthetic valve endocarditis (PVE) is a known complication of prosthetic valve implantation (PVI). Native valve endocarditis (INVE) without concurrent PVE, or isolated native valve endocarditis (INVE), after PVI is largely unheard of in literature. This review aims to identify the factors that predispose to INVE along with management and complications of INVE.MethodsA review of four major databases was carried out to identify the incidence of INVE after various PVIs. INVE was compared to PVE in terms of patient demographics, PVI characteristics, pathogen types, management approaches, and outcomes.ResultsINVE was found in 119/645 (18.4%) cases after transcatheter aortic valve implantation (TAVI) and 9/138 (6.5%) cases after surgical aortic valve implantation (SAVI). INVE case distributions in the TAVI cohort were 87/119 (73.1%) on mitral valves and 32/119 (26.9%) on right heart valves. Corevalve implants were more closely linked to INVE than to transcatheter aortic valve implant endocarditis (TAVIE) at 67/119 (56.3%) vs 240/526 (45.6%) (OR = 1.55, CI 1.02–2.29, p = 0.036). Surgery was performed less frequently in INVE than TAVIE at 9/119 (7.6%) vs 130/526 (24.7%) (RR = 0.31, CI 0.16–0.58, p = 0.001). In hospital mortalities were less frequent in INVE than TAVIE at 22/119 (18.5%) vs 170/526 (32.3%) (RR 0.65, CI 0.45–0.94, p = 0.015).ConclusionINVE makes up a measurable proportion of endocarditis cases after TAVI and frequently manifests on mitral valves. Compared to TAVIE, INVE is more likely to occur after Corevalve PVI, is amenable to medical therapy, and has lower rate of in hospital mortality. Surgical and non-aortic PVI based INVE is less frequently reported on and warrants investigation.Keywords: Isolated native valve endocarditis, Transcatheter aortic valve implantation, Surgical aortic valve implantation, Prosthetic valve implantation, Mitral endocarditis, Right heart endocarditis Key points Question: What are the patient characteristics, contributing factors, and outcomes of isolated native valve endocarditis (INVE) following prosthetic valve implantation? Findings: INVE is observed most frequently after Corevalve implants, notably in native mitral and right heart valves. INVE can be managed with pharmacotherapy and has lower rates of in hospital mortality compared to transcatheter endocarditis. Infrequently, it has also been reported after surgical aortic and mitral valve implants. Meaning: The development of INVE should be closely screened for after Corevalve implantation. Moreover, patients with INVE require close follow up as long term mortality can be high in the presence of heart failure and systemic infection. This phenomenon needs further study in non-aortic and non-transcatheter valve implant populations. Introduction Prosthetic valve endocarditis (PVE) is an established complication of mechanical and bioprosthetic valve placement [1], [2]. In general, infective endocarditis (IE) has a predilection for prosthetic valves over native valves given the nidus that the prostheses provide for bacterial attachment and infection [3], [4]. PVE also carries a higher mortality rate than does native valve endocarditis (NVE). NVE subsequent to PVE has also been described and is known to carry a poorer prognosis than isolated PVE [4], [8]. In the setting of prosthetic valve implantation (PVI), the development of isolated native valve endocarditis (INVE) without PVE is an unusual phenomenon. Select review studies have described instances of INVE after PVIs [1], [3], [6], [7], [9], [10], [11], [12]. Case reports have also described instances of INVE after atypical bacterial infections [18], [19], [20]. A comprehensive review detailing the specifics of INVE has not been performed in prior studies however. The purpose of this review is to report on the patient characteristics, contributing factors, management strategies, and outcomes in INVE cases observed after various PVIs including transcatheter and surgical valve implants. Methods This review is registered in PROSPERO under the link - https://www.crd.york.ac.uk/PROSPERO/view/CRD42023474991. Search strategy The databases of Pubmed, Embase, Cochrane Library, and Web of Science were searched for relevant studies without limitations on the year of study. The search was updated prior to submission. Search terms encompassed in the review included transcatheter valve implant, surgical valve implant, PVE, and NVE. Supplemental Tables 1–4 show the complete search strings. Diagnosis and distinction in valvular endocarditis The diagnosis of IE was based on symptoms/signs of IE with evidence of organism growth in serial blood cultures and echocardiographic evidence of any of the following lesions - vegetation, abscess, aneurysm, fistula, pseudoaneurysm, or dehiscence. Using both transthoracic and transesophageal echocardiography, distinctions between PVE, NVE, and nonvalvular IE were made based on the location of IE on a prosthetic valve only versus prosthetic and native valve versus native valve only versus non-valvular site. This method was used to identify transcatheter aortic valve implant endocarditis (TAVIE), surgical aortic valve implant endocarditis (SAVIE), non-aortic prosthetic IE, combined PVE and NVE, INVE, and nonvalvular IE. Study selection Supplemental Fig. 1 shows the PRISMA strategy for screening and exclusion. Study selection and data extraction were done independently by 2 authors. No limits were placed on study date or design except that conference abstracts, editorials, and commentaries were excluded. Case reports, case series, and meta analyses where included were done for reference purposes only and not for data analyses. Non-English studies were excluded. Review and cohort articles describing outcomes/results/events after PVI were included. After screening of abstracts, full texts were reviewed and, if meeting the criteria for INVE, were included for data extraction. References in these texts were also examined and included for data extraction if they met the criteria for INVE. Data extraction Articles in the final set were examined and data on several categories were identified. Specifically IE incidence after PVI, age groups affected, gender affected, comorbidities, PVI type, method of PVI, pathogens, left ventricular ejection fractions, treatment type, follow up periods, mortality rates, and causes of mortality were determined for PVE and INVE groups. Combined PVE and NVE cases were included in the PVE group. Nonvalvular IE cases were excluded. Data was acquired directly through articles, contact with the authors of the articles, and the IE after transcatheter aortic valve replacement (TAVR) registry [5]. All data are available in the tables with the manuscript. Statistical analysis All categorical variables were summarized by count (number and percentage). The total counts in the INVE and PVE groups were compared using Chi-square test. We subsequently estimated odds ratios (OR), relative risk (RR), and corresponding 95% confidence intervals (CIs). P-values were determined from group comparisons with assumptions met. Bonferri and False Discovery Rate (FDR) correction methods were utilized where multiple comparisons were done. Results Search outcomes The search yielded 952 studies after removal of duplicates in Covidence. In these 952 studies, abstracts that described the outcomes of PVI were identified and moved into full text review. Out of 196 full texts on PVI outcomes, 16 matched the criteria for INVE. These studies were manually reviewed for INVE populations from the same registries. References in these studies were also reviewed. Ultimately, INVE cases reporting non TAVIs and non SAVIs were excluded from data analyses since very few cases were identified. INVE cases from 4 studies on TAVI (Table 1) and 4 studies on SAVI (Supplemental Table 5) were included in the final analysis. The remaining 8 studies consisted of duplicate data already reported in the included 8 studies and therefore were not added to the final analysis. The included studies comprised of retrospective reviews and prospective cohorts. A p value less than 0.05 was considered significant. Table 1General information on TAVI. Details from the 4 included TAVI studies pertaining to the period, region, and design of each study. The TAVI population size and number of post TAVI endocarditis cases of each individual study and cumulatively of all 4 studies are also listed.CategoryPanagidesYunMangnerScisloCumulativePeriod of studyJune 2005–Nov 2020Jan 2012–July 2020June 2008–Apr 2017Jan 2010–Dec 2018RegionEurope, North America, and South AmericaCleveland Clinic, OhioHeart Center Dresden, GermanyMedical University Warsaw, PolandDesignMulti-center retrospectiveSingle-center retrospectiveSingle-center retrospectiveSingle-center retrospectiveTAVI group size20,0065911031120,486Number of IE cases in TAVI group (TAVIE + INVE)56810616645 General information on TAVI. Details from the 4 included TAVI studies pertaining to the period, region, and design of each study. The TAVI population size and number of post TAVI endocarditis cases of each individual study and cumulatively of all 4 studies are also listed. Risk of bias All 8 articles were of good quality based on assessment of selection, comparability, and exposure categories in the Newcastle Ottawa assessment. All articles achieved 4 starts in selection criteria, 2 stars in comparability criteria, and 3 starts in exposure criteria. The criteria and interpretation of the assessment are described in the Newcastle Ottawa scoring supplement. Notably some data on the categories of interest to our study were not reported; these data were marked as “unknown” or “?” in the supplemental tables. One study drew data from an international registry consisting of multicenter databases while remaining studies drew data from unicenter databases. The discrepancies in population selection and size raise the possibility that associations close to cutoff for significance (p < 0.05) may be stronger or weaker if comparable populations are analyzed. Moreover, associations that are borderline insignificant (p > 0.05) may also be stronger or weaker with larger populations. INVE after TAVI Table 2, Table 3 summarize the findings for TAVIE and TAVI-INVE groups respectively. Data on the timing between TAVI and development of INVE were not available. INVE was observed in 119/645 (18.4%) cases of valvular IE after TAVI. In both INVE and TAVIE, cases were more frequent in males at 56.3% and 55.5% respectively. Comorbidity rates in INVE and TAVIE were similar except that diabetes (DM) was present in 40.3% INVE vs 30.4% TAVIE (OR 1.55, CI 1.03–2.33, p = 0.038). Chronic obstructive pulmonary disease (COPD) was present in 29.4% INVE vs 20.2% TAVIE (OR 1.65, CI 1.05–2.58, p = 0.027). Chronic kidney disease (CKD) was present in 32.8% INVE vs 46.2% TAVIE (OR 0.57, CI 0.37–0.86, p = 0.008). However the Bonferri and FDR correction criteria showed these findings as non-significant. Table 2Summary of findings for TAVIE cohort. Number of TAVIE cases per category was identified in each individual study and then cumulatively for all 4 TAVI studies on far right column.CategoryPanagidesYunMangnerScisloCumulativeNumber of cases461/5688/1053/614/6526/645 (81.6%)Gender distribution Male253/4616/831/532/4292/526 (55.5%) Female208/4612/822/532/4234/526 (44.5%)Concurrent comorbidities DM129/4614/825/532/4160/526 (30.4%) COPD90/4615/89/532/4106/526 (20.2%) CKD213/4611/827/532/4243/526 (46.2%) Coronary/Peripheral0/4612/839/532/443/526 (8.2%) Atrial fibrillation201/4611/834/531/4237/526 (45.1%) Hypertension0/4617/80/532/49/526 (1.7%) Stroke38/4612/85/530/445/526 (8.6%) Heart failure0/4610/830/530/430/526 (5.7%) Pulmonary embolism2/4610/80/530/42/526 (0.4%) Prior endocarditis2/4613/828/530/433/526 (6.3%)TAVI type Corevalve199/4612/836/533/4240/526 (45.6%) Sapien262/4616/817/530/4285/526 (54.2%) Boston Lotus0/4610/80/531/41/526 (0.2%)TAVI access site Transfemoral397/4618/847/533/4455/526 (86.5%) Other64/4610/86/531/471/526 (13.5%)Causal pathogen Staphylococcus186/4614/820/532/4212/526 (40.3%) Streptococcus99/4612/86/531/4108/526 (20.5%) Enterococcus130/4612/821/531/4154/526 (29.3%) Other54/4610/86/532/462/526 (11.8%)Treatment Antibiotics359/4610/834/533/4396/526 (75.3%) Surgery102/4618/819/531/4130/526 (24.7%)Follow up in years21132Deaths in hospital141/461 deaths1/8 deaths28/53 deaths0/4 deaths170/526 (32.3%) deathsCauses of death0/461 IE24/461 septic shock38/461 heart failure33/461 renal failure11/461 system emboli26/461 bacteremia9/461 stroke0/8 IE0/8 septic shock0/8 heart failure0/8 renal failure0/8 system emboli0/8 bacteremia1/8 stroke6/53 IE8/53 septic shock3/53 heart failure5/53 renal failure 5/53 system emboli0/53 bacteremia1/53 stroke0/4 IE0/4 septic shock0/4 heart failure0/4 renal failure0/4 system emboli0/4 bacteremia0/4 stroke6/526 (1.1%) IE32/526 (6.1%) septic shock41/526 (7.8%) heart failure38/526 (7.2%) renal failure16/526 (3.1%) system emboli26/526 (4.9%) bacteremia11/526 (2.1%) strokeDeaths at follow up96/461 deaths0/8 deaths10/53 deaths3/4 deaths109/526 (20.7%) deathsCauses of death0/461 IE17/461 septic shock26/461 heart failure22/461 renal failure7/461 system emboli18/461 bacteremia6/461 stroke0/8 IE0/8 septic shock0/8 heart failure0/8 renal failure0/8 system emboli0/8 bacteremia0/8 stroke2/53 IE3/53 septic shock1/53 heart failure1/53 renal failure3/53 system emboli0/53 bacteremia0/53 stroke3/4 IE0/4 septic shock0/4 heart failure0/4 renal failure0/4 system emboli0/4 bacteremia0/4 stroke5/526 (1.0%) IE20/526 (3.8%) septic shock27/526 (5.1%) heart failure23/526 (4.4%) renal failure10/526 (1.9%) system emboli18/526 (3.4%) bacteremia6/526 (1.1%) stroke Summary of findings for TAVIE cohort. Number of TAVIE cases per category was identified in each individual study and then cumulatively for all 4 TAVI studies on far right column. Table 3Summary of findings for INVE cohort. Number of INVE cases per category was identified in each individual study and then cumulatively for all 4 TAVI studies on the far right column.CategoryPanagidesYunMangnerScisloCumulativeNumber of cases107/5682/108/612/6119/645 (18.4%)Gender distribution Male60/1071/25/81/267/119 (56.3%) Female47/1071/23/81/252/119 (43.7%)Concurrent comorbidity DM41/1071/25/81/248/119 (40.3%) COPD31/1071/23/80/235/119 (29.4%) CKD34/1070/24/81/239/119 (32.8%) Coronary/Peripheral0/1070/26/80/26/119 (5.0%) Atrial fibrillation47/1071/27/80/255/119 (46.2%) Hypertension0/1070/20/81/21/119 (0.8%) Stroke10/1070/21/80/211/119 (9.2%) Heart failure0/1070/26/80/26/119 (5.0%) Pulmonary embolism2/1070/20/80/22/119 (1.7%) Prior endocarditis3/1070/24/80/27/119 (>5.9%)TAVI type and location of INVE Corevalve expanding37/107 mitral19/107 right heart2/2 mitral0/2 right heart7/8 mitral0/8 right heart2/2 mitral0/2 right heart48/119 mitral (40.3%)19/119 right heart (16.0%) Sapien expanding38/107 mitral13/107 right heart0/2 mitral0/2 right heart1/8 mitral0/8 right heart0/2 mitral0/2 right heart39/119 mitral (32.8%)13/119 right heart (10.9%) Boston Lotus0/1070/20/80/20/119 (0.0%)TAVI access site Transfemoral96/1072/27/82/2107/119 (89.9%) Other11/1070/21/80/212/119 (10.1%)Causal pathogen Staphylococcus47/1071/23/82/253/119 (44.5%) Streptococcus28/1070/21/80/229/119 (24.4%) Enterococcus26/1070/23/81/230/119 (25.2%) Other8/1071/21/80/210/119 (8.4%)Treatment Antibiotics only101/1070/27/82/2110/119 (92.4%) Surgery6/1072/21/80/29/119 (7.6%)Follow up in years21132Total deaths in hospital21/107 deaths0/2 deaths1/8 deaths0/2 deaths22/119 (18.5%) deathsCauses of death0/107 IE5/107 septic shock5/107 heart failure4/107 renal failure3/107 system emboli4/107 bacteremia0/107 stroke0/2 IE0/2 septic shock0/2 heart failure0/2 renal failure0/2 system emboli0/2 bacteremia0/2 stroke0/8 IE1/8 septic shock0/8 heart failure0/8 renal failure0/8 system emboli0/8 bacteremia0/8 stroke0/2 IE0/2 septic shock0/2 heart failure0/2 renal failure0/2 system emboli0/2 bacteremia0/2 stroke0/119 (0.0%) IE6/119 (5.0%) septic shock5/119 (4.2%) heart failure4/119 (3.4%) renal failure3/119 (2.5%) system emboli4/119 (3.4%) bacteremia0/119 (0.0%) strokeTotal deaths at follow up34/107 deaths0/2 deaths4/8 deaths1/2 deaths39/119 (32.8%) deathsCauses of death0/107 IE9/107 septic shock8/107 heart failure6/107 renal failure5/107 system emboli6/107 bacteremia0/107 stroke0/2 IE0/2 septic shock0/2 heart failure0/2 renal failure0/2 system emboli 0/2 bacteremia 0/2 stroke1/8 IE1/8 septic shock0/8 heart failure2/8 renal failure0/8 system emboli0/8 bacteremia0/8 stroke0/2 IE0/2 septic shock0/2 heart failure1/2 renal failure0/2 system emboli0/2 bacteremia0/2 stroke1/119 (0.8%) IE10/119 (8.4%) septic shock8/119 (6.7%) heart failure9/119 (7.6%) renal failure5/119 (4.2%) system emboli6/119 (5.0%) bacteremia0/119 (0.0%) stroke Summary of findings for INVE cohort. Number of INVE cases per category was identified in each individual study and then cumulatively for all 4 TAVI studies on the far right column. Transfemoral access was utilized for TAVI prior to most cases of INVE and TAVIE with an insignificantly higher rate in the INVE group. Beta lactam antibiotic prophylaxis was carried out in at least 80% of both groups with other antibiotics contributing the remaining 20%. No concurrent infections were noted in either group. Moreover, there were few instances of prior endocarditis or prior valvular procedures in either group and where present occurred at comparable rates. Corevalves were more frequently associated with INVE than TAVIE at 67/119 (56.3%) vs 240/526 (45.6%) respectively (OR = 1.55, CI 1.02–2.29, p = 0.036) and this association was true after Type I error correction (Table 4). The valvular distributions of INVE were 87/119 (73.1%) on mitral valves and 32/119 (26.9%) on right heart valves. The specific right heart valve locations of the latter were not identifiable. Infections in INVE and TAVIE were from gram positive flora such as staphylococci, streptococci, and enterococci at comparable rates. The sources of these pathogens were unknown in most of the cases, although gastrointestinal and urinary tract were considered likely points. Surgery was performed less frequently in INVE vs TAVIE at 9/119 cases (7.6%) vs 130/526 cases (24.7%) (RR = 0.31, CI 0.16–0.58, p < 0.001). Table 4Statistical comparison of TAVIE and INVE. Comparing proportions of INVE and TAVIE cases in each category. Odds ratios (OR) and relative risks (RR) were based on INVE to TAVIE calculations. Chi square analyses were applied for P values and confidence intervals (CI). Bonferroni and FDR methods were applied based on variable number to adjust for Type I error.CategoryOR or RRP valueBonferroniFDRCIGender distributionMale to femaleOR = 1.030.876<0.050.8760.69–1.54Concurrent comorbidity DMOR = 1.550.0380.12671.03–2.33 COPDOR = 1.650.028<0.0050.12671.05–2.58 CKDOR = 0.570.0080.080.37–0.86 Coronary/Peripheral diseaseOR = 0.600.2490.4980.25–1.44 Atrial fibrillationOR = 1.050.8180.8730.70–1.56 HypertensionOR = 0.490.4970.8280.061–3.88 StrokeOR = 1.090.8100.8730.55–2.17 Heart failureOR = 0.880.7770.8730.36–2.16 Pulmonary embolismOR = 4.480.1360.340.62–32.12 Prior endocarditisOR = 0.930.8730.8730.40–2.17TAVI type Corevalve vs OtherOR = 1.530.036<0.050.0361.02–2.29TAVI access site Transfemoral vs OtherOR = 1.390.317<0.050.3170.73–2.66Causal pathogen StaphylococcusOR = 1.190.3970.3970.80–1.78 StreptococcusOR = 1.240.356<0.01250.3970.78–1.99 EnterococcusOR = 0.810.3750.3970.52–1.28 OtherOR = 0.690.2920.3970.34–1.38Treatment Surgery vs antibiotics onlyRR = 0.31<0.001<0.050.0010.16–0.58Mortality location In hospital vs follow-upRR = 0.650.015<0.050.0150.45–0.94Mortality causeEndocarditisRR = 0.190.250.5830.01–3.24Septic shockRR = 1.360.250.5830.81–2.30Heart failureRR = 0.850.550.770.48–1.48Renal failureRR = 0.940.84<0.0070.980.54–1.66System emboliRR = 1.360.430.7530.63–2.93BacteremiaRR = 1.000.990.990.52–1.94StrokeRR = 0.130.150.5830.08–2.07 Statistical comparison of TAVIE and INVE. Comparing proportions of INVE and TAVIE cases in each category. Odds ratios (OR) and relative risks (RR) were based on INVE to TAVIE calculations. Chi square analyses were applied for P values and confidence intervals (CI). Bonferroni and FDR methods were applied based on variable number to adjust for Type I error. Ultimately, TAVIE and INVE cases were followed for approximately 2 years. In hospital mortalities were less frequent in INVE vs TAVIE at 22/119 (18.5%) vs 170/526 (32.3%) respectively (RR 0.65, CI 0.45–0.94, p = 0.015). A Kaplan Meier survival curve could not be generated as data on time to mortality and incremental mortality over time was not available on all patients in the INVE group. Mortality rates due to any particular cause were similar across both groups in hospital and at follow up; the specific percentages attributed to each cause are described in Table 3. INVE after SAVI Supplemental Tables 5, 6, and 7 summarize the findings for SAVIE and SAVI-INVE groups respectively. INVE was observed in 9/138 (6.5%) cases after SAVI. Cases were reported more frequently in males than females. Comorbidities observed with both SAVIE and INVE included diabetes, hypertension, heart failure, mitral regurgitation, aortic regurgitation, prior endocarditis, prior valve surgery, and malignancy. In the SAVIE group, staphylococcus was source of infection in 44% of cases and surgical management was required in about one third of the cases. Mortality rates in the SAVIE group were 18% in hospital and 7% at follow up due to endocarditis complications. Mortality data on the INVE group was very limited. It should be noted that in 2 of the 9 INVE cases, one was a tricuspid INVE associated with rheumatic disease and the source of infection was the uninfected SAVI. The other case was a mitral INVE with infection suspected from cardiac catheterization and uninfected SAVI. A formal statistical analysis of the categories of interest in the SAVI INVE and SAVIE groups was not possible given the small sizes and incomplete data on the groups. One instance of mitral INVE after SAVI that was not included in the data analysis was a case report of a Brucella infection [19]. The patient was 58 year old male with history of severe aortic stenosis requiring SAVI. Details regarding antibiotic prophylaxis, surgical approach, prosthesis type, ejection fraction, and suspected cause of INVE were not provided. The patient was treated with antibiotic therapy alone without subsequent INVE complications and was alive at 1 year follow up. INVE in non-aortic prostheses A few studies in our search reported INVE subsequent to non-aortic prostheses. One study described a single case of mitral INVE subsequent to transcatheter pulmonic valve replacement [8]. In this retrospective single center study, the patient was a 54 year old female with history of end stage renal disease on dialysis, pulmonic stenosis, and pulmonic endocarditis requiring Sapien 3 prosthetic implantation. The prosthetic valve was free of infection and the dialysis line was determined to be the source for mitral INVE. The pathogen was methicillin sensitive staph aureus treated with antibiotics and surgical mitral replacement. The prognosis was good and patient was alive after 2 years of follow up. Two studies reported on aortic INVE subsequent to mitral PVI. One study was a cohort following patients after mitral surgical PVI [12]. A total of 9 patients were identified with 8 developing endocarditis on the mitral PVI and 1 developing aortic INVE. The details on this aortic INVE patient including the patient's age, gender, comorbidities, surgical approach of PVI, PVI type, source of INVE, infecting pathogen, and complications after treatment of INVE could not be identified. However, it was known that the patient was treated with antibiotic therapy alone without surgery. Moreover, the patient was followed for 10 years with INVE developing 8 years after PVI and died at follow up from endocarditis complications. The second study was a case report involving a 42 year old male with mitral PVI that had been done 4 years before aortic INVE [18]. Comorbidites included aortic valve regurgitation, rhemautic mitral disease, and mitral stenosis. He had undergone a St. Jude mitral valve replacement. The prosthesis type was unknown as was the source of INVE. The pathogen involved was Corynebacterium diphtheriae and he was treated with combined antibiotics + surgery. No complications were noted after aortic INVE and he was alive at follow up. Discussion INVE is a phenomenon that has been reported most often in mitral and right heart valves after TAVI. Cases of INVE in non-mitral and non TAVI prostheses have been reported less frequently. Given this discrepancy, it is not surprising that the INVE associations and outcomes here reflect what has been previously reported on mitral INVE after TAVI [1]. The cumulative findings in our study are consistent with prior study findings demonstrating the higher likelihood of mitral INVE after Corevalve TAVIs [1]. A hypothetical possibility on the significant association between self-expanding Corevalve TAVIs and INVE could be that Corevalves are in close proximity to other heart valves and therefore capable of infecting native valves, as has been suggested in prior studies [1], [13], [14], [15], [16], [17]. However, this correlation was weakly positive and requires investigation with a larger INVE cohort. While mechanisms in TAVI based mitral INVE have been explored, mechanisms for TAVI based non mitral INVE and non TAVI based INVE warrant further investigation. In this study, there were 32 cases of right heart INVE; these cases were closely associated with Corevalves and Sapien valves. However the pathogenesis of INVE in these cases is unknown. Moreover, a review of literature revealed 6 cases of non TAVI leading to left and right heart INVE. These cases were mitral INVE after Sapien transcatheter pulmonic valve implantation, aortic INVE after surgical mitral valve replacement, mitral INVE after aortic homograft, two mitral INVEs after an unknown aortic prosthesis, and tricuspid INVE after an unknown aortic prosthesis. Although IV drug use has an established role in right heart endocarditis, these cases of right heart INVE were not linked to drug use. These findings suggest that there are alternate mechanisms for non mitral INVE in the setting of both TAVIs and non TAVIs. As TAVIE presents a higher likelihood of serious complications after initial infection, the study supports the expected finding that mortalities were higher in hospital compared with INVE. The lower mortality at follow up could be explained on the basis that the TAVIE population is smaller at follow up and thus has fewer mortalities compared to the INVE population. Alternatively, TAVIE is treated more aggressively initially with surgery and those who survive may be less likely to have complications as compared to conservative management in INVE. By contrast, conservative management with antibiotics could raise the likelihood of infection seeding into the vasculature to reach other systems and increase risk of long term mortality. It has been demonstrated that the presence of concomitant heart failure, renal failure, and septic shock contributes to long term mortality in the INVE population [1], [21], [22], [23], [24], [25]. The utility of conservative vs surgical management in TAVIE and INVE populations with and without these comorbidities is an area for future exploration. Thus far, very few reviews have holistically examined the associations between INVE and the categories of interest in our study. Such reviews would have to identify many patients with this rare form of IE and acquire individual patient data pertaining to the categories of interest. On the other hand, smaller studies have more individual patient data on these categories but not enough power to make significant associations due to smaller cohorts. In this study, cases from only 4 studies fit the criteria for inclusion and most of them came from the IE After TAVI Registry. Thus the data was heavily skewed to create the impression that INVE is mostly a TAVI associated phenomenon. Our review is among the first to attempt a comprehensive analysis of this unusual phenomenon. It preliminarily suggests that the development of INVE after PVI is closely linked to PVI type, procedural aspects of PVI, and pathogen type. It is manageable with antibiotic therapy although prognosis correlates with the presence of heart failure, renal failure, and septic shock. The significance of surgical versus medical management in long term survival is unclear and warrants future investigation. Limitations There were some notable limitations in our study. First, only 16 studies fit the criteria for inclusion. Among TAVI studies, data was frequently acquired from the IE After TAVI Registry which after removal of duplicates limited the size of the TAVI INVE population. Moreover, the size of the SAVI INVE population was extremely small and this prevented any type of analysis on that subgroup. Overall, the discrepancies in these groups created the impression that INVE is a TAVI associated phenomenon when in reality data is lacking for a true comparison of the different PVIs. To this end, establishing the incidence, associations, and predictors for INVE requires more data and a larger population of INVE patients. A multivariable comparison would also be possible to conduct with additional data points and thereby account for confounding factors. A sensitivity analysis would also be possible with additional data. A second limitation in our analysis was the challenge of accounting for confounders. Although there were no concurrent infections and antibiotic prophylaxis was similar in TAVIE and TAVI INVE groups, performing a stratified analysis was challenging without data to compare the categories of interest. This could potentially change the significance of the associations seen in the study and would need to addressed using more raw data. Another limitation involved the nature of the included studies themselves. One study was a multicenter review made up of a cohort that represented several international patient populations. All other studies drew data from unique hospital centers, each representing different patient populations. The final analysis required making a generalization about the associations in different patient populations and these associations may be different if comparable populations had been available for study. Lastly, our study could not determine if studies excluded during full text review had unreported instances of INVE. As PVE is more common and studied more extensively than INVE, unreported INVE data could strengthen or weaken the associations in our study. Future research should be aimed towards acquiring explicit data from studies that have reported on INVE as well as studies that have not reported on the phenomenon. Conclusion INVE is a complication frequently observed in mitral valves after Corevalve TAVIs. It is amenable to medical management and has lower rates of in hospital mortality compared to TAVIE. Overall, data on INVE is very limited and a larger population based study addressing associated factors and outcomes is essential to reach formal conclusions. Findings on INVE after SAVI and INVE after non aortic PVI are also not well established and warrant study. CRediT authorship contribution statement Sujoy Khasnavis: Writing – review & editing, Writing – original draft, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Stefan Makrievski: Data curation, Formal analysis. Caroline Delbourgo Patton: Data curation. Majd Alhuarrat: Data curation. Shaunak Mangeshkar: Data curation. Robert Faillace: Supervision. Michael Grushko: Supervision. Ethical statement This submission did not require ethical oversight or approval from an IRB or other research approval organization. Ethics declaration Not applicable. Funding disclosure This research did not receive any specific grant from funding agencies in the public, commercial, or non-for-profit sectors. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.ahjo.2026.100788. Supplementary data Supplementary material Supplementary tables Supplementary Fig. 1 PRISMA search strategy. 1855 database results were narrowed using PRISMA protocol. After exclusion of 903 duplicates, 185 out of 941 remaining studies specifically addressed post PVI outcomes. Out of these 185 studies, 16 involved cases of INVE and were included in the final review (n = 16). References Associated Data Supplementary Materials Supplementary material Supplementary tables Supplementary Fig. 1 PRISMA search strategy. 1855 database results were narrowed using PRISMA protocol. After exclusion of 903 duplicates, 185 out of 941 remaining studies specifically addressed post PVI outcomes. Out of these 185 studies, 16 involved cases of INVE and were included in the final review (n = 16).